Journal article
A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
- Abstract:
-
OBJECTIVES: Thrombocytopenia is an independent adverse prognostic factor in patients with Myelodysplastic syndromes (MDS). Azacitidine, first-line treatment for the majority of patients with higher-risk MDS, is associated with aggravated thrombocytopenia during the first cycles. Eltrombopag is a novel thrombopoietin receptor agonist, which also has been shown to inhibit proliferation of leukaemia cell lines in vitro. This phase I clinical trial was designed to explore the safety and tolerabil...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- European journal of haematology
- Volume:
- 93
- Issue:
- 5
- Pages:
- 439-445
- Publication date:
- 2014-11-01
- DOI:
- EISSN:
-
1600-0609
- ISSN:
-
0902-4441
- Source identifiers:
-
471953
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:471953
- UUID:
-
uuid:14f0740f-41fc-417d-aa2a-5bfc1e2d5b95
- Local pid:
- pubs:471953
- Deposit date:
- 2014-08-22
Terms of use
- Copyright date:
- 2014
If you are the owner of this record, you can report an update to it here: Report update to this record